Hot Features
Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for... Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, an interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; and MDNA113, a tumor-targeting and activatable bifunctional anti-PD-1-IL-2 superkine for cancer. In addition, its preclinical products are MDNA209, an IL-2/IL-15 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host diseases, including transplant rejection; and MDNA413, an IL-4/IL-13 antagonist to inflammatory, asthma, and atopic dermatitis, as well as other allergic diseases. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.00175 | 0.637290604516 | 0.2746 | 0.3079 | 0.255 | 137310 | 0.28332663 | CS |
| 4 | -0.03121 | -10.1476134738 | 0.30756 | 0.32 | 0.25 | 73030 | 0.28668634 | CS |
| 12 | -0.18929 | -40.6515763251 | 0.46564 | 0.52988 | 0.25 | 87370 | 0.35660423 | CS |
| 26 | -0.42165 | -60.4083094556 | 0.698 | 0.755 | 0.25 | 81844 | 0.48239619 | CS |
| 52 | -0.38365 | -58.1287878788 | 0.66 | 1.43 | 0.25 | 83426 | 0.68618931 | CS |
| 156 | 0.11235 | 68.506097561 | 0.164 | 2.2 | 0.158 | 89484 | 0.98011692 | CS |
| 260 | -4.39365 | -94.0824411135 | 4.67 | 4.67 | 0.158 | 88821 | 0.98011692 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.